MA34771B1 - Formes cristallines - Google Patents

Formes cristallines

Info

Publication number
MA34771B1
MA34771B1 MA36066A MA36066A MA34771B1 MA 34771 B1 MA34771 B1 MA 34771B1 MA 36066 A MA36066 A MA 36066A MA 36066 A MA36066 A MA 36066A MA 34771 B1 MA34771 B1 MA 34771B1
Authority
MA
Morocco
Prior art keywords
varieties
modulation
sensitive
cells
determining
Prior art date
Application number
MA36066A
Other languages
Arabic (ar)
English (en)
Inventor
Lili Feng
Baoqing Gong
Piotr H Karpinski
Liladhar Murlidhar Waykole
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34771(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34771B1 publication Critical patent/MA34771B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des formes cristallines spécifiques de la 5 -chloro-n-(2-isopropoxy-5-méthyl-4-(pipéridin-4-ylphényl)-n-2-(isopropylsulfonyl)phényl)-2,4-diamine. La présente invention concerne en outre des procédés de préparation desdites formes cristallines, des compositions pharmaceutiques comprenant lesdites formes cristallines, et des procédés d'utilisation desdites formes cristallines et des compositions pharmaceutiques pour traiter une maladie.
MA36066A 2010-12-17 2013-06-28 Formes cristallines MA34771B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424194P 2010-12-17 2010-12-17
PCT/US2011/065030 WO2012082972A1 (fr) 2010-12-17 2011-12-15 Formes cristallines de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine

Publications (1)

Publication Number Publication Date
MA34771B1 true MA34771B1 (fr) 2013-12-03

Family

ID=45464892

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36066A MA34771B1 (fr) 2010-12-17 2013-06-28 Formes cristallines

Country Status (35)

Country Link
US (2) US9309229B2 (fr)
EP (3) EP2651918B1 (fr)
JP (1) JP5916752B2 (fr)
KR (4) KR20130130022A (fr)
CN (7) CN112125884A (fr)
AR (2) AR084309A1 (fr)
AU (1) AU2011343775B2 (fr)
BR (1) BR112013015000A2 (fr)
CA (1) CA2821102C (fr)
CL (1) CL2013001723A1 (fr)
CO (1) CO6801792A2 (fr)
CY (2) CY1119474T1 (fr)
DK (2) DK3121171T3 (fr)
EC (1) ECSP13012770A (fr)
ES (3) ES2643016T3 (fr)
GT (1) GT201300153A (fr)
HR (2) HRP20171477T1 (fr)
HU (1) HUE041845T2 (fr)
IL (1) IL226474A (fr)
LT (2) LT2651918T (fr)
MA (1) MA34771B1 (fr)
MX (1) MX338210B (fr)
MY (2) MY177742A (fr)
NZ (1) NZ610713A (fr)
PE (1) PE20140698A1 (fr)
PL (2) PL3121171T3 (fr)
PT (2) PT2651918T (fr)
RS (1) RS57771B1 (fr)
RU (2) RU2599785C3 (fr)
SG (2) SG10201510082XA (fr)
SI (2) SI2651918T1 (fr)
TN (1) TN2013000216A1 (fr)
TW (2) TWI576344B (fr)
WO (1) WO2012082972A1 (fr)
ZA (1) ZA201303599B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651918B1 (fr) 2010-12-17 2017-07-12 Novartis AG Formes cristallines de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
RU2675850C2 (ru) 2012-11-06 2018-12-25 Шанхай Фокон Фармасьютикал Ко Лтд Ингибиторы alk-киназы
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN105272921A (zh) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 一种制备Ceritinib的方法及其中间体化合物
CN105294649B (zh) * 2014-07-30 2019-05-14 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
CN105294650A (zh) * 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
ES2813726T3 (es) 2014-10-21 2021-03-24 Ariad Pharma Inc Formas cristalinas de 5-cloro-N4-[-2-(dimetilfosforilo)fenilo]-N2-{2-metoxi-4-[4-(4-metilpiperazina-1-ilo)piperidina-1- ilo]pirimidina-2,4-diamina
WO2016081538A1 (fr) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Formes solides de ceritinib et sels de ceux-ci
CN105601614A (zh) * 2014-11-21 2016-05-25 奥浦顿（上海）医药科技有限公司 一种色瑞替尼晶型及其制备方法
WO2016082795A1 (fr) * 2014-11-28 2016-06-02 苏州晶云药物科技有限公司 Forme cristalline i du ceritinib et son procédé de préparation
CN105622577A (zh) * 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
WO2016108123A2 (fr) * 2014-12-17 2016-07-07 Dr. Reddy’S Laboratories Limited Forme amorphe pure et dispersion solide amorphe de céritinib
WO2016098070A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
WO2016098042A1 (fr) * 2014-12-19 2016-06-23 Novartis Ag Utilisation du céritinib (ldk -378) dans le traitement de troubles médiés par fes ou fer, en particulier des troubles prolifératifs
WO2017016529A1 (fr) 2015-07-28 2017-02-02 Zentiva, K.S. Formes solides de ceritinib base libre
CN105061397B (zh) * 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
WO2017152858A1 (fr) * 2016-03-11 2017-09-14 苏州晶云药物科技有限公司 Forme cristalline de céritinib et procédé pour sa préparation
WO2017158619A1 (fr) 2016-03-15 2017-09-21 Natco Pharma Limited Procédé modifié pour la préparation de céritinib et de forme amorphe de céritinib
JP2019196359A (ja) * 2019-06-17 2019-11-14 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
US20230348443A1 (en) * 2020-01-17 2023-11-02 Shandong Xuanzhu Pharma Co., Ltd. Crystal form of polycyclic anaplastic lymphoma kinase inhibitor

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
EP1660458B1 (fr) * 2003-08-15 2012-01-25 Novartis AG 2, 4-pyrimidine diamines utiles dans le cadre du traitement de maladies neoplasiques, de troubles inflammatoires et de troubles du systeme immunitaire
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
UA100846C2 (uk) * 2006-12-08 2013-02-11 Айерем Елелсі Сполуки та композиція як інгібітори протеїнкінази
EP2091918B1 (fr) * 2006-12-08 2014-08-27 Irm Llc Composés et compositions inhibant la protéine kinase
WO2009032694A1 (fr) * 2007-08-28 2009-03-12 Dana Farber Cancer Institute Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse
EA017252B1 (ru) * 2007-08-28 2012-11-30 Айрм Ллк Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
EP2271630B1 (fr) * 2008-04-07 2016-03-23 Novartis AG Composés et compositions comme inhibiteurs de la protéine kinase
NO2300013T3 (fr) * 2008-05-21 2018-02-03
US20120142667A1 (en) * 2009-06-10 2012-06-07 Nigel Ramsden Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (zh) 2009-12-17 2015-04-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物
ME02973B (fr) 2010-12-17 2018-07-20 Reata Pharmaceuticals Inc Pyrazolyl- et pyrimidinyl-énones tricycliques en tant que modulateurs d'inflammation antioxydants
EP2651918B1 (fr) * 2010-12-17 2017-07-12 Novartis AG Formes cristallines de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
JP2014501246A (ja) 2010-12-17 2014-01-20 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌・殺カビ性アゾ環式アミド
CN105294650A (zh) 2014-08-01 2016-02-03 江苏奥赛康药业股份有限公司 一种Ceritinib化合物及其药物组合物
WO2016081538A1 (fr) 2014-11-18 2016-05-26 Teva Pharmaceuticals International Gmbh Formes solides de ceritinib et sels de ceux-ci
DE112015005255B4 (de) 2014-11-21 2023-10-26 Joyson Safety Systems Acquisition Llc Airbagmodul
CN105622577A (zh) 2014-11-29 2016-06-01 江苏先声药业有限公司 一种色瑞替尼的新晶型及其制备方法
US20170355768A1 (en) 2014-12-04 2017-12-14 Bristol-Myers Squibb Company Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
WO2016098070A1 (fr) 2014-12-19 2016-06-23 Novartis Ag Forme cristalline de la 5-chloro-n2-(2-isopropoxy-5-méthyl-4-pipéridin-4-yl-phényl)-n4-[2-(propane-2-sulfonyl)-phényl]-pyrimidine-2,4-diamine
WO2017016529A1 (fr) 2015-07-28 2017-02-02 Zentiva, K.S. Formes solides de ceritinib base libre
CN105061397B (zh) 2015-08-07 2018-01-02 武汉英普瑞医药科技有限公司 一种色瑞替尼的c型晶型及其制备方法与应用

Also Published As

Publication number Publication date
CN107056751A (zh) 2017-08-18
LT3121171T (lt) 2018-11-12
ZA201303599B (en) 2014-02-26
HRP20181737T1 (hr) 2018-12-28
CN106831716A (zh) 2017-06-13
CN112125884A (zh) 2020-12-25
HRP20171477T1 (hr) 2017-11-17
PE20140698A1 (es) 2014-06-11
SG190856A1 (en) 2013-07-31
AR122395A2 (es) 2022-09-07
EP3453708B1 (fr) 2021-10-27
RU2599785C2 (ru) 2016-10-20
TW201307299A (zh) 2013-02-16
ECSP13012770A (es) 2013-10-31
PL2651918T3 (pl) 2017-12-29
CY1119474T1 (el) 2018-04-04
CN106008462A (zh) 2016-10-12
IL226474A0 (en) 2013-07-31
ES2643016T3 (es) 2017-11-21
US20160175305A1 (en) 2016-06-23
AU2011343775A1 (en) 2013-07-18
RU2013132947A (ru) 2015-01-27
WO2012082972A1 (fr) 2012-06-21
EP3453708B8 (fr) 2022-03-16
GT201300153A (es) 2014-06-09
MX2013006952A (es) 2013-07-15
TN2013000216A1 (en) 2014-11-10
DK3121171T3 (en) 2018-12-10
EP3121171B1 (fr) 2018-08-15
RU2016136823A3 (fr) 2020-02-06
CL2013001723A1 (es) 2013-12-27
RU2599785C3 (ru) 2019-04-24
ES2696526T3 (es) 2019-01-16
IL226474A (en) 2016-03-31
LT2651918T (lt) 2017-10-10
KR20190022903A (ko) 2019-03-06
CY1121017T1 (el) 2019-12-11
EP2651918A1 (fr) 2013-10-23
CN114989139A (zh) 2022-09-02
RU2746159C2 (ru) 2021-04-08
PL3121171T3 (pl) 2019-01-31
PT3121171T (pt) 2018-11-27
US20130274279A1 (en) 2013-10-17
SI3121171T1 (sl) 2018-11-30
AR084309A1 (es) 2013-05-08
RS57771B1 (sr) 2018-12-31
NZ610713A (en) 2014-10-31
JP2013545812A (ja) 2013-12-26
KR20200039021A (ko) 2020-04-14
ES2905973T3 (es) 2022-04-12
AU2011343775B2 (en) 2015-12-03
TWI576344B (zh) 2017-04-01
BR112013015000A2 (pt) 2016-08-09
MX338210B (es) 2016-04-07
CA2821102C (fr) 2019-06-11
JP5916752B2 (ja) 2016-05-11
CO6801792A2 (es) 2013-11-29
RU2016136823A (ru) 2018-12-11
PT2651918T (pt) 2017-10-17
TW201629021A (zh) 2016-08-16
CA2821102A1 (fr) 2012-06-21
KR20180032680A (ko) 2018-03-30
SI2651918T1 (sl) 2017-10-30
TWI576343B (zh) 2017-04-01
US9309229B2 (en) 2016-04-12
HUE041845T2 (hu) 2019-05-28
KR102325775B1 (ko) 2021-11-12
SG10201510082XA (en) 2016-01-28
MY164810A (en) 2018-01-30
CN104262324A (zh) 2015-01-07
EP2651918B1 (fr) 2017-07-12
DK2651918T3 (en) 2017-10-23
EP3453708A1 (fr) 2019-03-13
MY177742A (en) 2020-09-23
EP3121171A1 (fr) 2017-01-25
CN103282359A (zh) 2013-09-04
KR20130130022A (ko) 2013-11-29

Similar Documents

Publication Publication Date Title
MA34771B1 (fr) Formes cristallines
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EP2410330A3 (fr) Procédés d'utilisation du récepteur GPR119 permettant d'identifier les composants utiles à l'augmentation de la masse osseuse chez un individu
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
MA33450B1 (fr) Dérivés d'oxazine et leur utilisation en tant qu'inhibiteurs de bace pour le traitement de troubles neurologiques
MA34299B1 (fr) Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
MA33492B1 (fr) Inhibiteurs de bace
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
MA30672B1 (fr) Utilisation de derives de l'azabicyclo hexane
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
WO2006102308A3 (fr) Antagonistes de bêta-lactamyl vasopressine v1b
MA35716B1 (fr) Formulations pharmaceutiques
ATE486601T1 (de) Verwendung von 3- (4-amino-1-oxo-1,3-dihydro- isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
EA200970532A1 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
WO2009155054A3 (fr) Modulateurs du récepteur 5-ht<sb>3</sb>, procédés de préparation et utilisation de ceux-ci
WO2009089263A3 (fr) Nouvelles compositions et procédés d'utilisation
MY167575A (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs